



: Mrs.CHANDRIKA N

Age/Gender

: 35 Y 4 M 4 D/F

UHID/MR No

: CMAR.0000329161

Visit ID

: CMAROPV731244

Ref Doctor Emp/Auth/TPA ID

: Dr.SELF : 248762263834 Collected

: 14/Oct/2023 08:39AM

Received

: 14/Oct/2023 11:11AM

Reported Status

: 14/Oct/2023 02:13PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY							
ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324							
Test Name Result Unit Bio. Ref. Range Method							

HAEMOGLOBIN	13	g/dL	12-15	Spectrophotometer
PCV	40.20	%	36-46	Electronic pulse & Calculation
RBC COUNT	4.52	Million/cu.mm	3.8-4.8	Electrical Impedenc
MCV	88.8	fL	83-101	Calculated
MCH	28.7	pg	27-32	Calculated
MCHC	32.3	g/dL	31.5-34.5	Calculated
R.D.W	13	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	8,040	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (I	DLC)			
NEUTROPHILS	58	%	40-80	Electrical Impedance
LYMPHOCYTES	31	%	20-40	Electrical Impedance
EOSINOPHILS	3.5	%	1-6	Electrical Impedance
MONOCYTES	7	%	2-10	Electrical Impedance
BASOPHILS	0.5	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	4663.2	Cells/cu.mm	2000-7000	Electrical Impedance
LYMPHOCYTES	2492.4	Cells/cu.mm	1000-3000	Electrical Impedance
EOSINOPHILS	281.4	Cells/cu.mm	20-500	Electrical Impedance
MONOCYTES	562.8	Cells/cu.mm	200-1000	Electrical Impedance
BASOPHILS	40.2	Cells/cu.mm	0-100	Electrical Impedance
PLATELET COUNT	326000	cells/cu.mm	150000-410000	Electrical impedend
ERYTHROCYTE SEDIMENTATION RATE (ESR)	23	mm at the end of 1 hour	0-20	Modified Westegrei method

RBCs: are normocytic normochromic

WBCs: are normal in total number with normal distribution and morphology.

PLATELETS: appear adequate in number.

Page 1 of 13







: Mrs.CHANDRIKA N

Age/Gender UHID/MR No : 35 Y 4 M 4 D/F : CMAR.0000329161

Visit ID

: CMAROPV731244

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID

: 248762263834

Collected

: 14/Oct/2023 08:39AM

Received

: 14/Oct/2023 11:11AM : 14/Oct/2023 02:13PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name

Result

Unit

Bio. Ref. Range

Method

HEMOPARASITES: negative

IMPRESSION: NORMOCYTIC NORMOCHROMIC BLOOD PICTURE.

Page 2 of 13

SIN No:BED230251927 NABL renewal accreditation under process







: Mrs.CHANDRIKA N

Age/Gender

: 35 Y 4 M 4 D/F

UHID/MR No Visit ID : CMAR.0000329161

Ref Doctor

: CMAROPV731244

Emp/Auth/TPA ID

: Dr.SELF : 248762263834 Collected

: 14/Oct/2023 08:39AM

Received

: 14/Oct/2023 11:11AM : 14/Oct/2023 04:39PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

Test Name Result Unit Bio. Ref. Range M	ethod
---	-------

BLOOD GROUP ABO AND RH FACTOR, WHOLE BLOOD EDTA				
BLOOD GROUP TYPE	AB	Microplate Hemagglutination		
Rh TYPE	Positive	Microplate Hemagglutination		

Page 3 of 13

SIN No:BED230251927

NABL renewal accreditation under process







: Mrs.CHANDRIKA N

Age/Gender

: 35 Y 4 M 4 D/F

UHID/MR No

: CMAR.0000329161

Ref Doctor

Visit ID

: CMAROPV731244

Emp/Auth/TPA ID

: Dr.SELF : 248762263834 Collected

: 14/Oct/2023 08:39AM

Received

: 14/Oct/2023 11:13AM : 14/Oct/2023 11:44AM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY	
----------------------------	--

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

Comment:

As per American Diabetes Guidelines, 2023

per rimerican Diabetes Guidelines, 2020			
Fasting Glucose Values in mg/dL	Interpretation		
70-100 mg/dL	Normal		
100-125 mg/dL	Prediabetes		
≥126 mg/dL	Diabetes		
<70 mg/dL	Hypoglycemia		

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Page 4 of 13

SIN No:PLF02040709

NABL renewal accreditation under process





Patient Name : Mrs.CHANDRIKA N

Age/Gender : 35 Y 4 M 4 D/F

UHID/MR No : CMAR.0000329161

Visit ID : CMAROPV731244

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : 248762263834

Collected : 14/Oct/2023 08:39AM

Received : 14/Oct/2023 10:44AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

: 14/Oct/2023 12:06PM

DEPARTMENT	OF BIOCHEMISTRY
------------	------------------------

Reported

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD EDTA	5.3	%	HPLC
ESTIMATED AVERAGE GLUCOSE (eAG) , WHOLE BLOOD EDTA	105	mg/dL	Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %		
NON DIABETIC	<5.7		
PREDIABETES	5.7 – 6.4		
DIABETES	≥ 6.5		
DIABETICS			
EXCELLENT CONTROL	6 – 7		
FAIR TO GOOD CONTROL	7 – 8		
UNSATISFACTORY CONTROL	8 – 10		
POOR CONTROL	>10		

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control

A: HbF >25%

B: Homozygous Hemoglobinopathy.

(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 5 of 13

SIN No:EDT230094573

NABL renewal accreditation under process





Patient Name : Mrs.CHANDRIKA N

Age/Gender : 35 Y 4 M 4 D/F

UHID/MR No : CMAR.0000329161

Visit ID : CMAROPV731244
Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : 248762263834

Collected : 14/Oct/2023 08:39AM

Received : 14/Oct/2023 10:46AM Reported : 14/Oct/2023 11:36AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY					
ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name Result Unit Bio. Ref. Range Method					

LIPID PROFILE , SERUM				
TOTAL CHOLESTEROL	183	mg/dL	<200	CHO-POD
TRIGLYCERIDES	74	mg/dL	<150	GPO-POD
HDL CHOLESTEROL	53	mg/dL	40-60	Enzymatic Immunoinhibition
NON-HDL CHOLESTEROL	130	mg/dL	<130	Calculated
LDL CHOLESTEROL	115.2	mg/dL	<100	Calculated
VLDL CHOLESTEROL	14.8	mg/dL	<30	Calculated
CHOL / HDL RATIO	3.45		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
III 1) I	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
INON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 6 of 13

SIN No:SE04511541

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telangana - 500 016 | www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744

APOLLO CLINICS NETWORK

Address: 323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka-560034







Patient Name : Mrs.CHANDRIKA N

Age/Gender : 35 Y 4 M 4 D/F UHID/MR No : CMAR.0000329161

Visit ID : CMAROPV731244

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : 248762263834 Collected : 14/Oct/2023 08:39AM

Received : 14/Oct/2023 10:46AM Reported

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

: 14/Oct/2023 11:36AM

DEPARTMENT OF BIOCHEMISTRY					
ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name Result Unit Bio. Ref. Range Method					

LIVER FUNCTION TEST (LFT) , SERUM				
BILIRUBIN, TOTAL	0.70	mg/dL	0.3–1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.12	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	0.58	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	28	U/L	<35	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	19.0	U/L	<35	IFCC
ALKALINE PHOSPHATASE	101.00	U/L	30-120	IFCC
PROTEIN, TOTAL	6.90	g/dL	6.6-8.3	Biuret
ALBUMIN	4.13	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	2.77	g/dL	2.0-3.5	Calculated
A/G RATIO	1.49		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with
- Disproportionate increase in AST, ALT compared with ALP.
- · Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.

3. Synthetic function impairment:

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Page 7 of 13







: Mrs.CHANDRIKA N

Age/Gender

: 35 Y 4 M 4 D/F

UHID/MR No Visit ID

: CMAR.0000329161

Ref Doctor

: CMAROPV731244

Emp/Auth/TPA ID

: Dr.SELF

: 248762263834

Collected

: 14/Oct/2023 08:39AM

Received

: 14/Oct/2023 10:46AM : 14/Oct/2023 11:36AM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name

Result

Unit

Bio. Ref. Range

Method

Page 8 of 13



THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE



Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telang www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744 na - 500 016 | APOLLO CLINICS NETWORK

Aduress: 323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka- 560034







: Mrs.CHANDRIKA N

Age/Gender

: 35 Y 4 M 4 D/F

UHID/MR No Visit ID : CMAR.0000329161

Ref Doctor

: CMAROPV731244

Emp/Auth/TPA ID

: Dr.SELF : 248762263834 Collected

: 14/Oct/2023 08:39AM

Received

: 14/Oct/2023 10:46AM : 14/Oct/2023 11:36AM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY					
ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT), SERUM				
CREATININE	0.67	mg/dL	0.72 – 1.18	JAFFE METHOD
UREA	18.50	mg/dL	17-43	GLDH, Kinetic Assay
BLOOD UREA NITROGEN	8.6	mg/dL	8.0 - 23.0	Calculated
URIC ACID	4.30	mg/dL	2.6-6.0	Uricase PAP
CALCIUM	9.80	mg/dL	8.8-10.6	Arsenazo III
PHOSPHORUS, INORGANIC	3.39	mg/dL	2.5-4.5	Phosphomolybdate Complex
SODIUM	138	mmol/L	136–146	ISE (Indirect)
POTASSIUM	4.7	mmol/L	3.5–5.1	ISE (Indirect)
CHLORIDE	107	mmol/L	101–109	ISE (Indirect)

Page 9 of 13



SIN No:SE04511541

 $NABL\ renewal\ accreditation\ under\ process$





: Mrs.CHANDRIKA N

Age/Gender

: 35 Y 4 M 4 D/F

UHID/MR No Visit ID : CMAR.0000329161

Ref Doctor

: CMAROPV731244

Emp/Auth/TPA ID

: Dr.SELF : 248762263834 Collected

: 14/Oct/2023 08:39AM

Received Reported : 14/Oct/2023 10:46AM : 14/Oct/2023 11:36AM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY	Y HEALTH ANNUAL	PLUS CHECK -	FEMALE - 2D ECHO - F	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

GAMMA GLUTAMYL TRANSPEPTIDASE	26.00	U/L	<38	IFCC	
(GGT) SERUM					

Page 10 of 13

SIN No:SE04511541

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Address: 323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka-560034







Patient Name : Mrs.CHANDRIKA N

Age/Gender : 35 Y 4 M 4 D/F UHID/MR No : CMAR.000032

UHID/MR No : CMAR.0000329161 Visit ID : CMAROPV731244

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : 248762263834

Collected : 14/Oct/2023 08:39AM

Received : 14/Oct/2023 10:46AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

: 14/Oct/2023 11:40AM

DEPARTMENT OF IMMUNOLOGY					
ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name Result Unit Bio. Ref. Range Method					

Reported

THYROID PROFILE TOTAL (T3, T4, TSH), SERUM					
TRI-IODOTHYRONINE (T3, TOTAL)	1.21	ng/mL	0.64-1.52	CMIA	
THYROXINE (T4, TOTAL)	13.62	μg/dL	4.87-11.72	CMIA	
THYROID STIMULATING HORMONE (TSH)	1.950	μIU/mL	0.35-4.94	CMIA	

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)			
First trimester	0.1 - 2.5			
Second trimester	0.2 - 3.0			
Third trimester	0.3 - 3.0			

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions		
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis		
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.		
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism		
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy		
Low	N	N	N	Subclinical Hyperthyroidism		
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism		
Low	N	High	High	Thyroiditis, Interfering Antibodies		
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes		
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma		

Page 11 of 13

SIN No:SPL23146800

NABL renewal accreditation under process





: Mrs.CHANDRIKA N

Age/Gender

: 35 Y 4 M 4 D/F

UHID/MR No Visit ID

: CMAR.0000329161

Ref Doctor

: CMAROPV731244

Emp/Auth/TPA ID

: Dr.SELF : 248762263834 Collected

: 14/Oct/2023 08:39AM

Received

: 14/Oct/2023 01:38PM : 14/Oct/2023 01:58PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF	CLINICAL	PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324	

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------

COMPLETE URINE EXAMINATION (CUE) ,	URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	5.5		5-7.5	DOUBLE INDICATOR
SP. GRAVITY	1.010		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GLUCOSE OXIDASE
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING REACTION
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	SODIUM NITRO PRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION
BLOOD	NEGATIVE		NEGATIVE	Peroxidase
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	LEUCOCYTE ESTERASE
CENTRIFUGED SEDIMENT WET MOUNT	AND MICROSCOPY			
PUS CELLS	1-2	/hpf	0-5	Microscopy
EPITHELIAL CELLS	2-3	/hpf	<10	MICROSCOPY
RBC	NIL	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 12 of 13

SIN No:UR2202134

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN - U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telangana - 500 016 | www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744

APOLLO CLINICS NETWORK

Address: 323/100/123, Doddathangur Village, Neeladri Main Road, Neeladri Nagar, Electronic city, Bengaluru, Karnataka-560034







: Mrs.CHANDRIKA N

Age/Gender

: 35 Y 4 M 4 D/F

UHID/MR No

: CMAR.0000329161

Visit ID

: CMAROPV731244

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : 248762263834

Collected

: 14/Oct/2023 08:38AM

Received Reported : 14/Oct/2023 11:01AM : 14/Oct/2023 01:43PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name

Result

Unit

Bio. Ref. Range

Method

URINE GLUCOSE(FASTING)

NEGATIVE

NEGATIVE

Dipstick

*** End Of Report ***

Result/s to Follow: PERIPHERAL SMEAR

DR.SHIVARAJA SHETTY
M.B.B.S,M.D(Biochemistry)
CONSULTANT BIOCHEMIST

Dr.Shobha Emmanuel M.B.B.S,M.D(Pathology) Consultant Pathologist Dr. Chinki Anupam M.B.B.S,M.D(Pathology) Consultant Pathologist

Page 13 of 13

SIN No:UF009607

NABL renewal accreditation under process